School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
School of Pharmacy, Guangxi Medical University, Nanning, Guangxi 530021, China.
J Ethnopharmacol. 2024 Sep 15;331:118265. doi: 10.1016/j.jep.2024.118265. Epub 2024 Apr 25.
Traditional Chinese Medicines (TCMs) have emerged as a promising complementary therapy in the management of prostate cancer (PCa), particularly in addressing resistance to Docetaxel (DTX) chemotherapy.
This review aims to elucidate the mechanisms underlying the development of resistance to DTX in PCa and explore the innovative approach of integrating TCMs in PCa treatment to overcome this resistance. Key areas of investigation include alterations in microtubule proteins, androgen receptor and androgen receptor splice variant 7, ERG rearrangement, drug efflux mechanisms, cancer stem cells, centrosome clustering, upregulation of the PI3K/AKT signaling pathway, enhanced DNA damage repair capability, and the involvement of neurotrophin receptor 1/protein kinase C.
With "Prostate cancer", "Docetaxel", "Docetaxel resistance", "Natural compounds", "Traditional Chinese medicine", "Traditional Chinese medicine compound", "Medicinal plants" as the main keywords, PubMed, Web of Science and other online search engines were used for literature retrieval.
Our findings underscore the intricate interplay of molecular alterations that collectively contribute to the resistance of PCa cells to DTX. Moreover, we highlight the potential of TCMs as a promising complementary therapy, showcasing their ability to counteract DTX resistance and enhance therapeutic efficacy.
The integration of TCMs in PCa treatment emerges as an innovative approach with significant potential to overcome DTX resistance. This review not only provides insights into the mechanisms of resistance but also presents new prospects for improving the clinical outcomes of patients with PCa undergoing DTX therapy. The comprehensive understanding of these mechanisms lays the foundation for future research and the development of more effective therapeutic interventions.
传统中药（TCM）已成为治疗前列腺癌（PCa）的一种有前途的辅助疗法，特别是在解决多西紫杉醇（DTX）化疗耐药方面。
本综述旨在阐明PCa 对 DTX 耐药性发展的机制，并探讨将 TCM 整合到 PCa 治疗中以克服这种耐药性的创新方法。研究的重点领域包括微管蛋白、雄激素受体和雄激素受体剪接变体 7、ERG 重排、药物外排机制、肿瘤干细胞、中心体聚集、PI3K/AKT 信号通路的上调、增强的 DNA 损伤修复能力以及神经营养因子受体 1/蛋白激酶 C 的参与。
以“前列腺癌”、“多西紫杉醇”、“多西紫杉醇耐药”、“天然化合物”、“中药”、“中药复方”、“药用植物”为主要关键词，使用 PubMed、Web of Science 等在线搜索引擎进行文献检索。
我们的研究结果强调了分子改变的复杂相互作用，这些改变共同导致了 PCa 细胞对 DTX 的耐药性。此外，我们强调了 TCM 作为一种有前途的辅助治疗方法的潜力，展示了它们抵抗 DTX 耐药性和增强治疗效果的能力。
将 TCM 整合到 PCa 治疗中是一种具有显著潜力的创新方法，可以克服 DTX 耐药性。本综述不仅提供了对耐药机制的深入了解，还为改善接受 DTX 治疗的 PCa 患者的临床结局提供了新的前景。对这些机制的全面理解为未来的研究和更有效的治疗干预措施的发展奠定了基础。
